Reversible binding of ethacrynic acid to human serum albumin: Difference circular dichroism study

Chirality

Volumn 11, Issue 1, 1999, Pages 33-38

  Bertucci, Carlo ^b   Nanni, Barbara ^b   Salvadori, Piero ^a  

^a UNIVERSITY OF PISA   (Italy)

^b NONE

Author keywords

Circular dichroism; Cys34 modified albumin; Ethacrynic acid; HSA binding; Interaction between drugs; Stereoselectivity

Indexed keywords

ETACRYNIC ACID; HUMAN SERUM ALBUMIN;

ABSORPTION SPECTROSCOPY; ARTICLE; CIRCULAR DICHROISM; DRUG PROTEIN BINDING; PRIORITY JOURNAL; SPECTROPHOTOMETER; STOICHIOMETRY;

ANTI-ANXIETY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BILIRUBIN; BINDING SITES; BINDING, COMPETITIVE; BIOLOGICAL MARKERS; CIRCULAR DICHROISM; DIAZEPAM; DIURETICS; ETHACRYNIC ACID; HUMANS; PHENYLBUTAZONE; PROTEIN BINDING; SERUM ALBUMIN;

EID: 0032927560     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-636X(1999)11:1<33::AID-CHIR6>3.0.CO;2-U     Document Type: Article

References (34)

1. Muller WE, Wollert U. Human serum albumin as a silent receptor for drugs and endogenous substances. Pharmacology 1979;19:59-67.
2. Peters T Jr. Serum albumin. Adv Protein Chem 1985;37:161-245.
3. Kragh-Hansen U. Molecular aspects of ligand binding to serum albumin. Pharmacol Rev 1981;33:17-53.
4. Fehske KJ, Mueller WE, Wollert U. The location of drug binding sites in human serum albumin. Biochem Pharmacol 1981;30:687-692.
5. He XM, Carter DC. Atomic structure and chemistry of human serum albumin. Nature 1992;358:209-215.
6. Carter DC, Ho JX. Structure of serum albumin. Adv Protein Chem 1994;45:153-203.
7. Kragh-Hansen U. Structure and ligand binding properties of human serum albumin. Dan Med Bull 1990;37:54-87.
8. Yamasaki K, Maruyama T, Kragh-Hansen U, Otagiri K. Characterisation of site I on human serum albumin: concept about the structure of a drug binding site. Biochim Biophys Acta 1996;1295:147-157.
9. Bertucci C, Salvadori P, Domenici E. Circular dichroism in the study of stereoselective binding of drug to serum proteins. In: Hassan YAE, Wainer IW, editors. The impact of stereochemistry on drug development and use. New York: John Wiley and Sons Inc.: 1997. p 521-543.
10. Domenici E, Bertucci C, Salvadori P, Felix G, Cahagne I, Motellier S, Wainer IW. Synthesis and chromatographic properties of an HPLC chiral stationary phase based upon human serum albumin. Chromatography 1990;29:170-176.
11. Wainer IW. Enantioselective high performance liquid affinity chromatography as a probe of ligand-biopolymer interactions: an overview of a different use for high performance liquid chromatographic chiral stationary phases. J Chromatogr 1994;666:221-234.
12. Vorum H, Fisker K, Otagiri M, Pedersen AO, Kragh-Hansen U. Calcium ion binding to clinically relevant chemical modifications of human serum albumin. Clin Chem 1995;41:1654-1661.
13. Bertucci C, Wainer IW. Improved chromatographic performance of a modified human albumin stationary phase. Chirality 1997;9:335-340.
14. Fehske KJ, Müller WE. High-affinity binding of ethacrynic acid is mediated by the two most important drug binding sites of human serum albumin. Pharmacology 1986;32:208-213.
15. Takamura N, Haruta A, Kodama H, Tsuruoka M, Yamasaki K, Suenaga A, Otagiri M. Mode of interaction of loop diuretics with human serum albumin and characterization of binding site. Pharm Res 1996;13:1015-1019.
16. Sellers EM, Koch-Weser J. Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids. Clin Pharmacol Ther 1970;11:524-529.
17. Koechel DA, Smith SA, Cafruny EJ. The interaction of ethacrynic acid, dihydroethacrynic acid and certain thiols adducts of ethacrynic acid with bovine serum albumin. J Pharmacol Exp Ther 1977;203:272-282.
18. Ascoli G, Bertucci C, Salvadori P. Stereospecific and competitive binding of drugs to human serum albumin: a different circular dichroism approach. J Pharm Sci 1995;84:137-141.
19. Rosen A. The measurement of binding constants using circular dichroism. Binding of phenylbutazone and oxyphenylbutazone. Biochem Pharmacol 1970;19:2075-2081.
20. Perrin JH, Nelson DA. Competitive binding of two drugs for a single binding site on albumin: a circular dichroic study. J Pharm Pharmacol 1973;25:125-130.
21. Roodsorp N, Sjöholm I. Determination of binding constants from continuous circular dichroism titration data by numerical analysis. Biochem Pharmacol 1976;25:2141-2145.
22. Narazaki R, Harada K, Sugii A, Otagiri M. Kinetic analysis of the covalent binding of captopril to human serum albumin. J Pharm Sci 1997;86:215-219.
23. Elwell ML, Shellman JA. Stability of Phage T4 lysozymes. I. Native properties and thermal stability of wild type and two mutant lysozymes. Biochimica et Biophisica Acta 1977;494:367-383.
24. Rosen A. The measurement of binding constants using circular dichroism. Biochem Pharmacol 1970;19:2075-2081.
25. Harding JJ. Nonenzymatic covalent posttranslational modification of proteins In Vivo. Adv Protein Chem 1985;37:247-334.
26. 34. FEBS Lett 1995;376:1-5.
27. Era S. Serum albumin: recent progress in the understanding of its structure and pathophysiology. Acta Sch Med Univ Gifu 1991;39:6-24.
28. Era S, Kuwata K, Imai H, Nakamura K, Hayashi T, Sogami M. Age-related change in redox state of human serum albumin. Biochim Biophys Acta 1995;1247:12-16.
29. Van Der Vliet A, Cross CE, Halliwell B, O'Neill CA. Plasma protein sulfhydryl oxidation: effect of low molecular weight thiols. Methods Enzymol 1995;251(Biothiols, Part A):448-455.
30. Narazaki R, Hamada M, Harada K, Otagiri M. Covalent binding between bucillamine derivatives and human serum albumin. Pharmacol Res 1996;13:1317-1321.
31. 34 by ethacrynic acid: structural characterisation and binding properties. J Pharm Biomed Anal, in press.
32. Kragh-Hansen U. Octanoate binding to the indole- and benzodiazepine-binding region of human serum albumin. Biochem J 1991;273:641-644.
33. Honoré B. Conformational changes in human serum albumin induced by ligand binding. Pharmacol. Toxicol. 1990;66:1-26.
34. Spector AA. Plasma albumin as a lipoprotein. Biochem Dis 1986;11 (Biochem Biol Plasma Lipoproteins):247-279.